<article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xmlns:xlink="http://www.w3.org/1999/xlink"
         xmlns:mml="http://www.w3.org/1998/Math/MathML"
         dtd-version="1.0"
         article-type="research-article">
   <front>
      <journal-meta>
         <journal-id journal-id-type="jstor">intejhealcarefin</journal-id>
         <journal-id journal-id-type="jstor">j100925</journal-id>
         <journal-title-group>
            <journal-title>International Journal of Health Care Finance and Economics</journal-title>
         </journal-title-group>
         <publisher>
            <publisher-name>Kluwer Academic Publishers</publisher-name>
         </publisher>
         <issn pub-type="ppub">13896563</issn>
         <issn pub-type="epub">15736962</issn>
         <custom-meta-group/>
      </journal-meta>
      <article-meta>
         <article-id pub-id-type="jstor">3528840</article-id>
         <title-group>
            <article-title>Setting Prices for New Vaccines (in Advance)</article-title>
         </title-group>
         <contrib-group>
            <contrib contrib-type="author">
               <string-name>
                  <given-names>Thomas G.</given-names>
                  <surname>McGuire</surname>
               </string-name>
            </contrib>
         </contrib-group>
         <pub-date>
            <day>1</day>
            <month>9</month>
            <year>2003</year>
         </pub-date>
         <volume xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table">3</volume>
         <issue xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table">3</issue>
         <issue-id>i280699</issue-id>
         <fpage>207</fpage>
         <lpage>224</lpage>
         <page-range>207-224</page-range>
         <permissions>
            <copyright-statement>Copyright 2003 Kluwer Academic Publishers</copyright-statement>
         </permissions>
         <self-uri xlink:href="https://www.jstor.org/stable/3528840"/>
         <abstract>
            <p>New vaccines have high social value, but the incentives to firms to develop new vaccines appear to be weak. This paper recommends setting a procurement price for a new vaccine prior to the vaccine's development, with the price based on the anticipated benefits from developing the vaccine. The price paid to vaccine suppliers is not equal to the price charged to either consumers supplied by public or private sources, so a high price does not choke off demand. A supply price leading to efficient levels of investment can be figured in advance based on cost-effectiveness analyses. Calculations indicate that efficient vaccine prices are considerably above prices currently paid for new vaccines.</p>
         </abstract>
         <kwd-group>
            <kwd>Vaccines</kwd>
            <kwd>Procurement</kwd>
            <kwd>Innovation</kwd>
         </kwd-group>
         <custom-meta-group>
            <custom-meta>
               <meta-name>lang</meta-name>
               <meta-value>eng</meta-value>
            </custom-meta>
         </custom-meta-group>
      </article-meta>
   </front>
   <back>
      <ref-list>
         <title>Notes</title>
         <ref id="d1e132a1310">
            <label>1</label>
            <mixed-citation id="d1e139" publication-type="other">
Schwartz and Orenstein (2001)</mixed-citation>
            <mixed-citation id="d1e145" publication-type="other">
Mercer Management Consulting (1995)</mixed-citation>
            <mixed-citation id="d1e151" publication-type="other">
Arnould and
DeBrock (2002).</mixed-citation>
         </ref>
         <ref id="d1e161a1310">
            <label>2</label>
            <mixed-citation id="d1e168" publication-type="other">
JOM (2000)</mixed-citation>
            <mixed-citation id="d1e174" publication-type="other">
Scherer (2000).</mixed-citation>
         </ref>
         <ref id="d1e181a1310">
            <label>3</label>
            <mixed-citation id="d1e188" publication-type="other">
Laffont (1994)</mixed-citation>
            <mixed-citation id="d1e194" publication-type="other">
Rogerson (1994).</mixed-citation>
         </ref>
         <ref id="d1e201a1310">
            <label>4</label>
            <mixed-citation id="d1e208" publication-type="other">
Kremer concludes (2000a, p. 23)</mixed-citation>
         </ref>
         <ref id="d1e216a1310">
            <label>7</label>
            <mixed-citation id="d1e223" publication-type="other">
Struck (1996)</mixed-citation>
         </ref>
         <ref id="d1e230a1310">
            <label>13</label>
            <mixed-citation id="d1e237" publication-type="other">
Kremer's (2000a)</mixed-citation>
         </ref>
         <ref id="d1e244a1310">
            <label>19</label>
            <mixed-citation id="d1e251" publication-type="other">
Newmann et al. (2000)</mixed-citation>
            <mixed-citation id="d1e257" publication-type="other">
(Murphy and Topel, 1999)</mixed-citation>
            <mixed-citation id="d1e263" publication-type="other">
Miller and Falkow (2002)</mixed-citation>
         </ref>
         <ref id="d1e270a1310">
            <label>20</label>
            <mixed-citation id="d1e277" publication-type="other">
Lichtenberg, 2002</mixed-citation>
         </ref>
         <ref id="d1e284a1310">
            <label>21</label>
            <mixed-citation id="d1e291" publication-type="other">
Finkelstein's (2002)</mixed-citation>
         </ref>
      </ref-list>
      <ref-list>
         <title>References</title>
         <ref id="d1e307a1310">
            <mixed-citation id="d1e311" publication-type="book">
Amould, R. and L. DeBrock. (2002). "An Overview of the Market for Vaccines in the United States." Paper
Prepared for the Committee on Evaluation of Vaccine Purchase Financing in the United States, Institute of
Medicine, September, 2002.<person-group>
                  <string-name>
                     <surname>Amould</surname>
                  </string-name>
               </person-group>
               <source>An Overview of the Market for Vaccines in the United States</source>
               <year>2002</year>
            </mixed-citation>
         </ref>
         <ref id="d1e340a1310">
            <mixed-citation id="d1e344" publication-type="book">
Axnick, N. W., S. M. Shavell and J. J. Witte. (1969). "Benefits Due to Immunization Against Measles." Public
Health Reports 84, 673-675.<person-group>
                  <string-name>
                     <surname>Axnick</surname>
                  </string-name>
               </person-group>
               <comment content-type="section">Benefits Due to Immunization Against Measles</comment>
               <fpage>673</fpage>
               <volume>84</volume>
               <source>Public Health Reports</source>
               <year>1969</year>
            </mixed-citation>
         </ref>
         <ref id="d1e379a1310">
            <mixed-citation id="d1e383" publication-type="journal">
Berndt, E., et al. (2002). "The Medical Treatment of Depression, 1991-1996: Productive Inefficiency, Expected
Outcome Variations, and Price Indicies." Journal of Health Economics 12(3), 373-396.<person-group>
                  <string-name>
                     <surname>Berndt</surname>
                  </string-name>
               </person-group>
               <issue>3</issue>
               <fpage>373</fpage>
               <volume>12</volume>
               <source>Journal of Health Economics</source>
               <year>2002</year>
            </mixed-citation>
         </ref>
         <ref id="d1e418a1310">
            <mixed-citation id="d1e422" publication-type="book">
Cutler, D., M. McClellan, J. Newhouse and D. Remler. (2001). "Pricing Heart Attack Treatments." In E.
Berndt and D. Cutler (eds.), Medical Care Output and Productivity. Univeristy of Chicago Press, pp. 305-
362.<person-group>
                  <string-name>
                     <surname>Cutler</surname>
                  </string-name>
               </person-group>
               <comment content-type="section">Pricing Heart Attack Treatments</comment>
               <fpage>305</fpage>
               <source>Medical Care Output and Productivity</source>
               <year>2001</year>
            </mixed-citation>
         </ref>
         <ref id="d1e458a1310">
            <mixed-citation id="d1e462" publication-type="journal">
Cohen, J. (2002). "U.S. Vaccine Supply Falls Seriously Short." Science 295, 1998-2001.<object-id pub-id-type="jstor">10.2307/3076247</object-id>
               <fpage>1998</fpage>
            </mixed-citation>
         </ref>
         <ref id="d1e475a1310">
            <mixed-citation id="d1e479" publication-type="book">
Finkelstein, A. (2002). "Health Policy and Technological Change: Evidence from the Vaccine Industry." NBER
Working Paper, July.<person-group>
                  <string-name>
                     <surname>Finkelstein</surname>
                  </string-name>
               </person-group>
               <source>Health Policy and Technological Change: Evidence from the Vaccine Industry</source>
               <year>2002</year>
            </mixed-citation>
         </ref>
         <ref id="d1e504a1310">
            <mixed-citation id="d1e508" publication-type="journal">
Freed, G. L., S. J. Clark and A. E. Cowan. (2002). "State Level Perspectives on Immunization Policies, Practices
and Program Financing for the 1990's." American Journal of Preventive Medicine 19(3S), 32-44.<person-group>
                  <string-name>
                     <surname>Freed</surname>
                  </string-name>
               </person-group>
               <issue>3S</issue>
               <fpage>32</fpage>
               <volume>19</volume>
               <source>American Journal of Preventive Medicine</source>
               <year>2002</year>
            </mixed-citation>
         </ref>
         <ref id="d1e543a1310">
            <mixed-citation id="d1e547" publication-type="journal">
Freed, G. L., M. M. Davis, M. C. Andreae, S. Bass and H. Weinblatt. (2002). "Reimbursement for Prevnar: A
Modern-Day Version of Hercules and the Hydra." Pediatrics 110(2), 399-400.<person-group>
                  <string-name>
                     <surname>Freed</surname>
                  </string-name>
               </person-group>
               <issue>2</issue>
               <fpage>399</fpage>
               <volume>110</volume>
               <source>Pediatrics</source>
               <year>2002</year>
            </mixed-citation>
         </ref>
         <ref id="d1e582a1310">
            <mixed-citation id="d1e586" publication-type="journal">
Grabowski, H. G. and J. Vernon. (2000). "The Distribution of Sales Revenue from Pharmaceutical Innovation."
PharmacoEconomics, 18(suppl.), xx-xx.<person-group>
                  <string-name>
                     <surname>Grabowski</surname>
                  </string-name>
               </person-group>
               <fpage>xx</fpage>
               <volume>18</volume>
               <source>PharmacoEconomics</source>
               <year>2000</year>
            </mixed-citation>
         </ref>
         <ref id="d1e618a1310">
            <mixed-citation id="d1e622" publication-type="book">
Hay, J. W. and D. Zammit. (2002). "Vaccine Policy Perspectives: Market Strategies." Paper Prepared for the
Committee on Evaluation of Vaccine Purchase Financing in the United States, Institute of Medicine, September.<person-group>
                  <string-name>
                     <surname>Hay</surname>
                  </string-name>
               </person-group>
               <source>Vaccine Policy Perspectives: Market Strategies</source>
               <year>2002</year>
            </mixed-citation>
         </ref>
         <ref id="d1e648a1310">
            <mixed-citation id="d1e652" publication-type="book">
Institute of Medicine. (2000). Calling the Shots: Immunization Finance Policies and Practicies. Washington, DC:
National Academy Press.<person-group>
                  <string-name>
                     <surname>Institute of Medicine</surname>
                  </string-name>
               </person-group>
               <source>Calling the Shots: Immunization Finance Policies and Practicies</source>
               <year>2000</year>
            </mixed-citation>
         </ref>
         <ref id="d1e677a1310">
            <mixed-citation id="d1e681" publication-type="journal">
Jacobs, R. J. and A. S. Meyerhoff. (2001). "Comparative Cost Effectiveness of Varicella, Hepatitus A, and Pneu-
mococcal Conjugate Vaccines." Preventive Medicine 33, 639-645.<person-group>
                  <string-name>
                     <surname>Jacobs</surname>
                  </string-name>
               </person-group>
               <fpage>639</fpage>
               <volume>33</volume>
               <source>Preventive Medicine</source>
               <year>2001</year>
            </mixed-citation>
         </ref>
         <ref id="d1e713a1310">
            <mixed-citation id="d1e717" publication-type="book">
Kremer, M. (2000a). "Creating Markets for New Vaccines-Part I: Rational." in Jaffe, Lerner and Stem (eds.),
Innovation Policy and the Economy.<person-group>
                  <string-name>
                     <surname>Kremer</surname>
                  </string-name>
               </person-group>
               <comment content-type="section">Creating Markets for New Vaccines-Part I: Rational</comment>
               <source>Innovation Policy and the Economy</source>
               <year>2000</year>
            </mixed-citation>
         </ref>
         <ref id="d1e746a1310">
            <mixed-citation id="d1e750" publication-type="book">
Kremer, M. (2000b). "Creating Markets for New Vaccines-Part II: Design Issues." in Jaffe, Lerner and Stem
(eds.), Innovation Policy and the Economy.<person-group>
                  <string-name>
                     <surname>Kremer</surname>
                  </string-name>
               </person-group>
               <comment content-type="section">Creating Markets for New Vaccines-Part II: Design Issues</comment>
               <source>Innovation Policy and the Economy</source>
               <year>2000</year>
            </mixed-citation>
         </ref>
         <ref id="d1e779a1310">
            <mixed-citation id="d1e783" publication-type="journal">
Laffont, J. J. (1994). "The New Economics of Regulation Ten Years After." Econometrica 623, 507-537.<person-group>
                  <string-name>
                     <surname>Laffont</surname>
                  </string-name>
               </person-group>
               <fpage>507</fpage>
               <volume>623</volume>
               <source>Econometrica</source>
               <year>1994</year>
            </mixed-citation>
         </ref>
         <ref id="d1e812a1310">
            <mixed-citation id="d1e816" publication-type="book">
Lichtenberg, F. R. (2002). "Trends in Vaccine Prices." Paper Prepared for the Committee on Evaluation of Vaccine
Purchase Financing in the United States, Institute of Medicine, September.<person-group>
                  <string-name>
                     <surname>Lichtenberg</surname>
                  </string-name>
               </person-group>
               <comment content-type="section">Trends in Vaccine Prices</comment>
               <source>Paper Prepared for the Committee on Evaluation of Vaccine Purchase Financing in the United States</source>
               <year>2002</year>
            </mixed-citation>
         </ref>
         <ref id="d1e846a1310">
            <mixed-citation id="d1e850" publication-type="journal">
Lichtenberg, F. R. (1996). "Do (More and Better) Drugs Keep People Out of Hospitals?" American Economic
Review 86(2), 384-388.<object-id pub-id-type="jstor">10.2307/2118157</object-id>
               <fpage>384</fpage>
            </mixed-citation>
         </ref>
         <ref id="d1e866a1310">
            <mixed-citation id="d1e870" publication-type="journal">
Mercer Management Consulting. (1995). "Report on the Vaccine Industry." Commissioned for the Department of
Health and Human Services, June 14.<person-group>
                  <string-name>
                     <surname>Mercer Management Consulting</surname>
                  </string-name>
               </person-group>
               <issue>June 14</issue>
               <source>Commissioned for the Department of Health and Human Services</source>
               <year>1995</year>
            </mixed-citation>
         </ref>
         <ref id="d1e899a1310">
            <mixed-citation id="d1e903" publication-type="book">
Mercer Management Consulting. (2002). "Lessons Learned: New Procurement Strategies for Vaccines." Final
Report to the GAVI Board.<person-group>
                  <string-name>
                     <surname>Mercer Management Consulting</surname>
                  </string-name>
               </person-group>
               <source>Lessons Learned: New Procurement Strategies for Vaccines</source>
               <year>2002</year>
            </mixed-citation>
         </ref>
         <ref id="d1e928a1310">
            <mixed-citation id="d1e932" publication-type="journal">
Miller, H. (2002). "An Indefensible Epidemic." The Wall Street Journal August 19.<person-group>
                  <string-name>
                     <surname>Miller</surname>
                  </string-name>
               </person-group>
               <source>The Wall Street Journal August 19</source>
               <year>2002</year>
            </mixed-citation>
         </ref>
         <ref id="d1e954a1310">
            <mixed-citation id="d1e958" publication-type="book">
Murphy, K. M. and R. Topel. (1999). The Economic Value of Medical Research. Chicago: University of Chicago
Press.<person-group>
                  <string-name>
                     <surname>Murphy</surname>
                  </string-name>
               </person-group>
               <source>The Economic Value of Medical Research</source>
               <year>1999</year>
            </mixed-citation>
         </ref>
         <ref id="d1e983a1310">
            <mixed-citation id="d1e987" publication-type="journal">
Neumann, P. J., et al. (2000). "Are Pharmaceuticals Cost-Effective?" Health Affairs March/April.<person-group>
                  <string-name>
                     <surname>Neumann</surname>
                  </string-name>
               </person-group>
               <issue>March</issue>
               <source>Are Pharmaceuticals Cost-Effective?</source>
               <year>2000</year>
            </mixed-citation>
         </ref>
         <ref id="d1e1013a1310">
            <mixed-citation id="d1e1017" publication-type="book">
Pauly, M. V. and B. E. Cleff. (1996). "The Economics of Vaccine Policy: A Summary of the Issues." in Pauly et al.
(eds.), Supplying Vaccines: An Economic Analysis of the Critical Issues. Amsterdam: IOS Press.<person-group>
                  <string-name>
                     <surname>Pauly</surname>
                  </string-name>
               </person-group>
               <comment content-type="section">The Economics of Vaccine Policy: A Summary of the Issues</comment>
               <source>Supplying Vaccines: An Economic Analysis of the Critical Issues</source>
               <year>1996</year>
            </mixed-citation>
         </ref>
         <ref id="d1e1046a1310">
            <mixed-citation id="d1e1050" publication-type="book">
Philipson, T. (2000). "Economic Epidemiology and Infectious Diseases." In A. J. Culyer and J. P. Newhouse (eds.),
Handbook of Health Economics. Elsevier Science, B.V.<person-group>
                  <string-name>
                     <surname>Philipson</surname>
                  </string-name>
               </person-group>
               <comment content-type="section">Economic Epidemiology and Infectious Diseases</comment>
               <source>Handbook of Health Economics</source>
               <year>2000</year>
            </mixed-citation>
         </ref>
         <ref id="d1e1079a1310">
            <mixed-citation id="d1e1083" publication-type="book">
PhRMA. (2001). "Industry Profile 2001." http://www.phrma.org/publicatoins/publicatoins/profile01/.<person-group>
                  <string-name>
                     <surname>PhRMA</surname>
                  </string-name>
               </person-group>
               <source>Industry Profile 2001</source>
               <year>2001</year>
            </mixed-citation>
         </ref>
         <ref id="d1e1105a1310">
            <mixed-citation id="d1e1109" publication-type="journal">
Rogerson, W. (1994). "Economic Incentives and the Defense Procurement Process." Journal of Economic Per-
spectives 8(4), 65-90.<object-id pub-id-type="jstor">10.2307/2138339</object-id>
               <fpage>65</fpage>
            </mixed-citation>
         </ref>
         <ref id="d1e1125a1310">
            <mixed-citation id="d1e1129" publication-type="journal">
Rappuoli, R., H. I. Miller and S. Faldow. (2002). "The Intangible Value of Vaccination." Science 297, 937-939.<person-group>
                  <string-name>
                     <surname>Rappuoli</surname>
                  </string-name>
               </person-group>
               <fpage>937</fpage>
               <volume>297</volume>
               <source>Science</source>
               <year>2002</year>
            </mixed-citation>
         </ref>
         <ref id="d1e1158a1310">
            <mixed-citation id="d1e1162" publication-type="book">
Russell, L. B. (1986). Is Prevention Better than Cure? Washington, DC: Brookings Institution.<person-group>
                  <string-name>
                     <surname>Russell</surname>
                  </string-name>
               </person-group>
               <source>Is Prevention Better than Cure?</source>
               <year>1986</year>
            </mixed-citation>
         </ref>
         <ref id="d1e1185a1310">
            <mixed-citation id="d1e1189" publication-type="book">
Salkever, D. and R. Frank. (1996). "Economic Issues in Vaccine Purchase Arrangements." In Pauly et al. (eds.),
Supplying Vaccines: An Economic Analysis of the Critical Issues. Amsterdam: IOS Press.<person-group>
                  <string-name>
                     <surname>Salkever</surname>
                  </string-name>
               </person-group>
               <comment content-type="section">Economic Issues in Vaccine Purchase Arrangements</comment>
               <source>Supplying Vaccines: An Economic Analysis of the Critical Issues</source>
               <year>1996</year>
            </mixed-citation>
         </ref>
         <ref id="d1e1218a1310">
            <mixed-citation id="d1e1222" publication-type="book">
Scherer, F. M. (2000). "The Pharmaceutical Industry." In A. J. Culyer and J. P. Newhouse (eds.), Handbook of
Health Economics. Elsevier Science, B.V.<person-group>
                  <string-name>
                     <surname>Scherer</surname>
                  </string-name>
               </person-group>
               <comment content-type="section">The Pharmaceutical Industry</comment>
               <source>Handbook of Health Economics</source>
               <year>2000</year>
            </mixed-citation>
         </ref>
         <ref id="d1e1251a1310">
            <mixed-citation id="d1e1255" publication-type="journal">
Scherer F. M. (2001). "The Link Between Gross Profitability and Pharmaceutical R&amp;D Spending." Health Affairs
26(3), 216-221.<person-group>
                  <string-name>
                     <surname>Scherer</surname>
                  </string-name>
               </person-group>
               <issue>3</issue>
               <fpage>216</fpage>
               <volume>26</volume>
               <source>Health Affairs</source>
               <year>2001</year>
            </mixed-citation>
         </ref>
         <ref id="d1e1290a1310">
            <mixed-citation id="d1e1294" publication-type="journal">
Spencer, J. (2002). "States Relax Child Vaccine Rules as Medicine Cabinets Go Bare." The Wall Street Journal
August 7.<person-group>
                  <string-name>
                     <surname>Spencer</surname>
                  </string-name>
               </person-group>
               <source>The Wall Street Journal August 7</source>
               <year>2002</year>
            </mixed-citation>
         </ref>
         <ref id="d1e1319a1310">
            <mixed-citation id="d1e1323" publication-type="journal">
Schwartz, B. and W. A. Orenstein. (2001). "Vaccination Policies and Programs: The Federal Government's Rolein
Making the System Work." Primary Care 28(4), 697-711.<person-group>
                  <string-name>
                     <surname>Schwartz</surname>
                  </string-name>
               </person-group>
               <comment content-type="series title">4</comment>
               <fpage>697</fpage>
               <volume>28</volume>
               <source>Primary Care</source>
               <year>2001</year>
            </mixed-citation>
         </ref>
         <ref id="d1e1358a1310">
            <mixed-citation id="d1e1362" publication-type="book">
Stratton, K. R., J. S. Durch and R. S. Lawrence (eds.). (2000). Vaccines for the 21st Century: A Tool for Decision-
making. Washington, DC: Institute of Medicine, National Academy Press.<person-group>
                  <string-name>
                     <surname>Stratton</surname>
                  </string-name>
               </person-group>
               <source>Vaccines for the 21st Century: A Tool for Decisionmaking</source>
               <year>2000</year>
            </mixed-citation>
         </ref>
         <ref id="d1e1388a1310">
            <mixed-citation id="d1e1392" publication-type="journal">
Struck, M. (1996). "Vaccine R&amp;D Success Rates and Development Times." Nature and Biotechnology (14),
591-593.<person-group>
                  <string-name>
                     <surname>Struck</surname>
                  </string-name>
               </person-group>
               <fpage>591</fpage>
               <volume>14</volume>
               <source>Nature and Biotechnology</source>
               <year>1996</year>
            </mixed-citation>
         </ref>
         <ref id="d1e1424a1310">
            <mixed-citation id="d1e1428" publication-type="journal">
Tandon, P. (1982). "Optimal Patents with Compulsory Licensing." Journal of Political Economy.<object-id pub-id-type="jstor">10.2307/1831366</object-id>
            </mixed-citation>
         </ref>
         <ref id="d1e1438a1310">
            <mixed-citation id="d1e1442" publication-type="journal">
Weisbrod, B. A. (1971). "Costs and Benefits of Medical Research: A Case Study of Poliomyelitis." Journal of
Political Economy 79(3), 527-544.<object-id pub-id-type="jstor">10.2307/1830770</object-id>
               <fpage>527</fpage>
            </mixed-citation>
         </ref>
         <ref id="d1e1458a1310">
            <mixed-citation id="d1e1462" publication-type="journal">
Weniger, B. G., et al. (1998). "Addressing the Challenges to Immunization Practice with an Economic Algorithm
for Vaccine Selection." Vaccine 16(19), 1885-1897.<person-group>
                  <string-name>
                     <surname>Weniger</surname>
                  </string-name>
               </person-group>
               <issue>19</issue>
               <volume>16</volume>
               <source>Vaccine</source>
               <year>1998</year>
            </mixed-citation>
         </ref>
      </ref-list>
   </back>
</article>
